Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Depression present in late life and midlife significantly increased the risk for all-cause dementia based on pooled hazard ratios (hazard ratios, 1.95 and 1.56, respectively). HealthDay News — ...

There was no significant sex differences in toddlers with autism spectrum disorder across 17 of 18 measures, including symptom severity, receptive and expressive language, and social attention.

A quality improvement strategy can improve electronic health record-based screening for depression and anxiety in people with epilepsy.

HealthDay News — Military service does not appear to increase the risk of depression, according to a study published online May 29 in BMJ Military Health.

Spinal cord stimulation can reduce pain and restore nerve function among patients with diabetic peripheral neuropathy.

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Shifting patterns in ischemic stroke mortality and death locations across US populations highlight disparities and end-of-life care needs.

The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

Patients with Alzheimer disease and cognitive impairment with delayed REM sleep patterns have increased levels of brain amyloid and tau.

Central hypersomnolence disorders, such as narcolepsy type 2 and idiopathic hypersomnia, are associated with reduced health-related quality of life.

Maternal self-efficacy demonstrated a significant moderating effect on the association between infant sleep and maternal well-being.